Company has raised $41 million to date for immuno-therapy technology and has dual research centers in San Diego and Singapore
ImmunoScape, a biotech startup, said Tuesday that it has raised $14 million in venture capital funding to further its work toward the discovery of novel, cancer-specific T-cell receptors that better enable targeted oncology treatments.
The funding round was led by existing investor Anzu Partners, with participation from Amgen Ventures and EDBI, a Singapore-based global investor. It opened its San Diego lab last year.ImmunoScape is developing platform technology aimed at discovering and profiling rare cancer-specific T-cell receptors — proteins on immune cells that bind to abnormal cells in the body, like those of viruses or cancer. The immune cells then attack the rogue cells to help fight infections and diseases.
“Their unique high-throughput T-cell receptor discovery and evaluation platform has an unprecedented capacity to test millions of human T-cells against hundreds of cancer antigens,” said David Michael, managing partner at Anzu Partners.